Generalized pustular psoriasis may be caused or triggered by various factors, including genetic mutations, infections, and certain medications. Generalized pustular psoriasis (GPP) is a severe ...

More information: Jamie L.W. Rhoads et al, Real-world clinical characteristics and treatment patterns of generalized pustular psoriasis flares, Journal of the American Academy of Dermatology (2025 ...

WEDNESDAY, April 16, 2025 (HealthDay News) -- Patients with generalized pustular psoriasis (GPP) experience frequent flares, and treatment alterations of off-label agents are frequently observed ...

Dear stakeholders, For information, the company have advised that they are no longer pursuing a Marketing Authorisation Application from the Medicines and Healthcare products Regulatory Agency (MHRA) ...

A new study found that 57.6% of patients with psoriasis achieved super responder status with guselkumab, characterised by complete skin clearance at week 20. Bio-naive status and lower comorbidity ...

India Bolton, 25, doesn't always have visible psoriasis flares. But there are times when her psoriasis becomes so severe that she barely feels like herself. Below, she shares how she's learned to ...

Patients with generalized pustular psoriasis continued to experience frequent flares that were often uncontrolled by traditional off-label therapies, according to a study. A group of researchers ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. The leading ...

New research links ultra-processed food intake to higher psoriasis risk, even after accounting for genetics, BMI, and lifestyle, highlighting the potential of dietary changes in preventing chronic ...

Psoriasis is a disease that causes itchy, dry patches on your skin. Up to 40% of people with psoriasis have symptoms before they're 16 years old, and 10% get it before they're 10. Children can ...

German drugmaker Boehringer Ingelheim has its first regulatory approval for spesolimab, its antibody therapy for rare and life-threatening skin disorder generalised pustular psoriasis (GPP), in ...